title: [Combined anti-EGFR and anti-HER2 monoclonal antibodies: preclinical efficacy in the treatment of pancreatic cancer].
authors.forename: Christel
authors.initials: C
authors.lastname: Larbouret
authors.forename: Bruno
authors.initials: B
authors.lastname: Robert
authors.forename: Isabelle
authors.initials: I
authors.lastname: Teulon
authors.forename: David
authors.initials: D
authors.lastname: Azria
authors.forename: André
authors.initials: A
authors.lastname: Pèlegrin
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D019281:Dimerization; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000276:immunology; D010190:Pancreatic Neoplasms / Q000276:immunology / Q000628:therapy*; D000077544:Panitumumab; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000276:immunology; D000068878:Trastuzumab; D023041:Xenograft Model Antitumor Assays
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D066246:ErbB Receptors; D009363:Neoplasm Proteins; D000077544:Panitumumab; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C512478:EGFR protein, human; C485206:pertuzumab; C520777:matuzumab